Cagrilintide

Quick Facts

Introduction

Cagrilintide is a long-acting synthetic analogue of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. While most of the recent attention in metabolic research has centered on the incretin hormones, amylin represents a distinct and complementary satiety pathway, which is why cagrilintide is studied both on its own and alongside GLP-1 receptor agonists such as Semaglutide.

Native amylin acts after meals to promote a feeling of fullness, slow the rate at which the stomach empties, and suppress excessive glucagon secretion. Its native form is unstable and prone to aggregation, which historically limited its usefulness as a research tool. Cagrilintide was engineered to overcome both problems — improved stability and a much longer duration of action — making it practical to study on a once-weekly schedule.

This profile covers what cagrilintide is, the structural modifications that stabilize and prolong it, its amylin-receptor mechanism, the satiety and body-weight research it appears in, and how it compares with incretin-based compounds. Related entries are catalogued in the peptide database, and the GLP-1 reference compound is discussed under Semaglutide.

What is Cagrilintide?

Cagrilintide is a synthetic amylin analogue built on a modified amylin/calcitonin-derived backbone. Native human amylin readily forms insoluble amyloid-like aggregates — a property that complicates both its biology and its use as a research compound. Cagrilintide's sequence was redesigned to resist aggregation while preserving the receptor activity that drives satiety.

Like other long-acting metabolic peptides, cagrilintide carries a fatty-acid (acyl) side chain that promotes reversible binding to serum albumin. This albumin tethering protects the peptide from rapid clearance and provides a slow-release depot, extending its half-life into the range studied for once-weekly administration — the same strategy that gives Semaglutide its long duration.

Molecular and structural characteristics

Cagrilintide is a roughly 37-residue acylated peptide containing the intramolecular disulfide-bonded loop characteristic of the amylin/calcitonin family. The key structural objectives in its design were twofold: suppressing the amyloidogenic tendency of native amylin through targeted substitutions, and extending duration through the albumin-binding acyl chain.

The acyl moiety is the most consequential pharmacokinetic addition. By tethering the peptide to albumin it transforms the half-life far more than it changes receptor-binding chemistry — the same principle seen across the modern long-acting metabolic peptides.

Mechanism of action

Cagrilintide acts on the amylin receptor system, which is formed when the calcitonin receptor associates with one of several receptor activity-modifying proteins (RAMPs). This combination converts the calcitonin receptor into a receptor selective for amylin, and cagrilintide is studied as an agonist at these complexes. It also retains affinity for the calcitonin receptor itself.

Functionally, amylin-receptor agonism is associated with several effects studied in metabolic research: enhanced satiety signaling in the hindbrain, slowed gastric emptying, and suppression of postprandial glucagon. Importantly, amylin's satiety mechanism is distinct from the GLP-1 pathway, acting through different receptors and brain regions — the reason researchers describe the two as complementary rather than redundant.

This complementarity is the central research theme for cagrilintide. Because amylin and GLP-1 reduce food intake through separate circuits, combining cagrilintide with a GLP-1 receptor agonist such as Semaglutide is studied for an additive or synergistic effect on appetite — a pairing investigated as a fixed-ratio combination in clinical research.

• Agonism at amylin receptors (calcitonin receptor + RAMP complexes).
• Enhanced hindbrain satiety signaling, distinct from GLP-1 circuits.
• Slowed gastric emptying and suppressed postprandial glucagon.
• Complementary action when combined with GLP-1 receptor agonists.

Satiety and body-weight research applications

Cagrilintide's primary research context is body weight. Studied as a once-weekly amylin analogue, it has been associated with meaningful reductions in body weight in study populations with overweight or obesity, with the effect attributed to reduced energy intake driven by enhanced satiety rather than to increased energy expenditure.

The mechanism is studied as satiety-pathway reinforcement: amylin is a hormone the body already releases after meals, so cagrilintide amplifies an existing post-prandial fullness signal rather than imposing an unrelated pathway. This framing parallels how incretin agonists reinforce the gut's own post-meal hormones and links cagrilintide to the broader weight-research compounds catalogued in the peptide database.

Combination research with GLP-1 agonists

The most-discussed aspect of cagrilintide research is its combination with the GLP-1 receptor agonist semaglutide. Because amylin and GLP-1 suppress appetite through distinct receptors and neural circuits, a fixed-ratio co-formulation has been studied to test whether the two mechanisms produce greater reductions in food intake and body weight together than either does alone.

This dual-hormone strategy reflects a broader theme in modern metabolic research: rather than maximizing a single pathway, investigators study complementary mechanisms in combination. The same logic underlies multi-receptor single molecules such as Tirzepatide and Retatrutide, though cagrilintide approaches it by pairing two separate peptides rather than engineering one molecule to hit multiple receptors.

Comparison: Cagrilintide vs Semaglutide vs Retatrutide

Cagrilintide is mechanistically distinct from the incretin compounds it is often studied alongside. Semaglutide is a single GLP-1 agonist, and Retatrutide is a triple GIP/GLP-1/glucagon agonist; cagrilintide instead works through the separate amylin-receptor pathway.

Because the amylin and GLP-1 pathways are complementary, cagrilintide is frequently studied together with Semaglutide rather than in opposition to it. Full entries for each compound are in the peptide database.

Half-life and pharmacokinetic considerations

Cagrilintide's defining pharmacokinetic feature is a long half-life supporting once-weekly administration, a consequence of its albumin-binding fatty-acid chain and aggregation-resistant backbone. This distinguishes it sharply from native amylin and from the earlier short-acting amylin analogue pramlintide, which required dosing with meals.

As with other long-acting metabolic peptides, the slow approach to steady state is the rationale behind gradual titration in studies: stepping exposure up over weeks is examined as a way to limit the gastrointestinal effects, particularly nausea, that accompany rapid amylin-receptor engagement.

Reconstitution and handling considerations

Lyophilized cagrilintide is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken to protect the peptide. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized cagrilintide is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled.

Research limitations

Cagrilintide is an investigational compound, and much of the highest-profile data come from research on its combination with semaglutide rather than from cagrilintide alone, which complicates attributing effects to amylin agonism specifically. Gastrointestinal effects are the most commonly reported in studies, and long-term safety and durability remain active research questions. It is described here strictly for research reference.

• Much prominent data come from combination research, not monotherapy.
• Gastrointestinal effects are the most common in study populations.
• Long-term safety and durability of effect remain under study.
• Reported effects are dose-, titration-, and duration-dependent.

Frequently Asked Questions

Related Research Profiles

References

1. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021.Source
2. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021.Source
3. Hay DL, et al. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015.Source